Irritable Bowel Syndrome (IBS) - Market Insight, Epidemiology and Market Forecast - 2028

Name: Irritable Bowel Syndrome (IBS) - Market Insight, Epidemiology and Market Forecast - 2028
Brand: DelveInsight
SKU: I64871FB7DFEN
Price: 6250 USD
Availability: InStock

January 2019 | 100 pages | ID: I64871FB7DFEN
DelveInsight

US$ 6,250.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer

Checkout Later

Need Help? Ask a Question

This report can be delivered to the clients within 7-10 Business Days

DelveInsight's 'Irritable Bowel Syndrome (IBS) - Market Insight, Epidemiology and Market Forecast - 2028' report provides a detailed analysis of the Irritable Bowel Syndrome (IBS) epidemiology and market outlook for the 7MM.

MARKETS COVERED

United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2016-2028

Irritable Bowel Syndrome (IBS) Understanding and Treatment Algorithm

The market report provides the overview of the Irritable Bowel Syndrome (IBS) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.
Irritable Bowel Syndrome (IBS) Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Irritable Bowel Syndrome (IBS) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.
Irritable Bowel Syndrome (IBS) Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.
Irritable Bowel Syndrome (IBS) Market Outlook

The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Irritable Bowel Syndrome (IBS) market.
Irritable Bowel Syndrome (IBS) Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.
Irritable Bowel Syndrome (IBS) Report Insights

Patient Population in Irritable Bowel Syndrome (IBS)
Therapeutic Approaches in Irritable Bowel Syndrome (IBS)
Irritable Bowel Syndrome (IBS) Pipeline Analysis
Irritable Bowel Syndrome (IBS) Market Size and Trends
Irritable Bowel Syndrome (IBS) Market Opportunities
Impact of upcoming Therapies in Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome (IBS) Report Key Strengths

10 Year Forecast
7MM Coverage
Epidemiology Segmentation
Drugs Uptake
Highly Analyzed Market
Key Cross Competition

Irritable Bowel Syndrome (IBS) Report Assessment

Current Treatment Practices in Irritable Bowel Syndrome (IBS)
Unmet Needs in Irritable Bowel Syndrome (IBS)
Market Attractiveness
Market Drivers and Barriers

KEY BENEFITS

The report will help to develop Business Strategies by understanding the trends shaping and driving the Irritable Bowel Syndrome (IBS) market
Organize sales and marketing efforts by identifying the best opportunities for Irritable Bowel Syndrome (IBS) market
To understand the future market competition in the Irritable Bowel Syndrome (IBS) market.

1. REPORT INTRODUCTION

2. IRRITABLE BOWEL SYNDROME (IBS) MARKET OVERVIEW AT A GLANCE

2.1. Market Share Distribution of Irritable Bowel Syndrome (IBS) in 2016
2.2. Market Share Distribution of Irritable Bowel Syndrome (IBS) in 2028

3. DISEASE BACKGROUND AND OVERVIEW: IRRITABLE BOWEL SYNDROME (IBS)

3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment

4. EPIDEMIOLOGY AND PATIENT POPULATION

4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Irritable Bowel Syndrome (IBS) in 7MM
4.3. Total Prevalent Patient Population of Irritable Bowel Syndrome (IBS) in 7MM – By Countries

5. EPIDEMIOLOGY OF IRRITABLE BOWEL SYNDROME (IBS) BY COUNTRIES

5.1. United States
  5.1.1. Assumptions and Rationale
  5.1.2. Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS)
  5.1.3. Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS)
  5.1.4. Sex- Specific Cases of the Irritable Bowel Syndrome (IBS)
  5.1.5. Diagnosed Cases of the Irritable Bowel Syndrome (IBS)
  5.1.6. Treatable Cases of the Irritable Bowel Syndrome (IBS)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
  5.4.1. Assumptions and Rationale
  5.4.2. Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS)
  5.4.3. Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS)
  5.4.4. Sex- Specific Cases of the Irritable Bowel Syndrome (IBS)
  5.4.5. Diagnosed Cases of the Irritable Bowel Syndrome (IBS)
  5.4.6. Treatable Cases of the Irritable Bowel Syndrome (IBS)
5.5. France
  5.5.1. Assumptions and Rationale
  5.5.2. Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS)
  5.5.3. Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS)
  5.5.4. Sex- Specific Cases of the Irritable Bowel Syndrome (IBS)
  5.5.5. Diagnosed Cases of the Irritable Bowel Syndrome (IBS)
  5.5.6. Treatable Cases of the Irritable Bowel Syndrome (IBS)
5.6. Italy
  5.6.1. Assumptions and Rationale
  5.6.2. Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS)
  5.6.3. Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS)
  5.6.4. Sex- Specific Cases of the Irritable Bowel Syndrome (IBS)
  5.6.5. Diagnosed Cases of the Irritable Bowel Syndrome (IBS)
  5.6.6. Treatable Cases of the Irritable Bowel Syndrome (IBS)
5.7. Spain
  5.7.1. Assumptions and Rationale
  5.7.2. Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS)
  5.7.3. Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS)
  5.7.4. Sex- Specific Cases of the Irritable Bowel Syndrome (IBS)
  5.7.5. Diagnosed Cases of the Irritable Bowel Syndrome (IBS)
  5.7.6. Treatable Cases of the Irritable Bowel Syndrome (IBS)
5.8. United Kingdom
  5.8.1. Assumptions and Rationale
  5.8.2. Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS)
  5.8.3. Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS)
  5.8.4. Sex- Specific Cases of the Irritable Bowel Syndrome (IBS)
  5.8.5. Diagnosed Cases of the Irritable Bowel Syndrome (IBS)
  5.8.6. Treatable Cases of the Irritable Bowel Syndrome (IBS)
5.9. Japan
  5.9.1. Assumptions and Rationale
  5.9.2. Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS)
  5.9.3. Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS)
  5.9.4. Sex- Specific Cases of the Irritable Bowel Syndrome (IBS)
  5.9.5. Diagnosed Cases of the Irritable Bowel Syndrome (IBS)
  5.9.6. Treatable Cases of the Irritable Bowel Syndrome (IBS)

6. CURRENT TREATMENT & MEDICAL PRACTICES

6.1. Treatment Algorithm
6.2. Treatment Guidelines

7. UNMET NEEDS OF THE IRRITABLE BOWEL SYNDROME (IBS)

8. MARKETED THERAPIES

8.1. Drug A: Company
  8.1.1. Drug Description
  8.1.2. Mechanism of Action
  8.1.3. Regulatory Milestones
  8.1.4. Advantages & Disadvantages
  8.1.5. Product Profile
8.2. Drug B: Company
  8.2.1. Drug Description
  8.2.2. Mechanism of Action
  8.2.3. Regulatory Milestones
  8.2.4. Advantages & Disadvantages
  8.2.5. Product Profile

9. PIPELINE THERAPIES – AT A GLANCE

10. KEY CROSS COMPETITION

11. EMERGING THERAPIES FOR IRRITABLE BOWEL SYNDROME (IBS)

11.1. Drug C: Company
  11.1.1. Drug Description
  11.1.2. Clinical Trials Details
  11.1.3. Safety and Efficacy Profile
  11.1.4. Advantages & Disadvantages
  11.1.5. Pipeline Development Activities
  11.1.6. Product Profile
11.2. Drug D: Company
  11.2.1. Drug Description
  11.2.2. Clinical Trials Details
  11.2.3. Safety and Efficacy Profile
  11.2.4. Advantages & Disadvantages
  11.2.5. Pipeline Development Activities
  11.2.6. Product Profile

12. IRRITABLE BOWEL SYNDROME (IBS): 7MM MARKET ANALYSIS

12.1. 7MM Market Size of Irritable Bowel Syndrome (IBS)
12.2. 7MM Percentage Share of drugs marketed for Irritable Bowel Syndrome (IBS)
12.3. 7MM Market Sales of Irritable Bowel Syndrome (IBS) by Products

13. IRRITABLE BOWEL SYNDROME (IBS): COUNTRY-WISE MARKET ANALYSIS

13.1. United States
  13.1.1. Market Size of Irritable Bowel Syndrome (IBS) in United States
  13.1.2. Percentage Share of drugs marketed for Irritable Bowel Syndrome (IBS) in United States
  13.1.3. Market Sales of Irritable Bowel Syndrome (IBS) by Products in United States
  13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
  13.2.1. Germany
    13.2.1.1. Market Size of Irritable Bowel Syndrome (IBS) in Germany
    13.2.1.2. Percentage Share of drugs marketed for Irritable Bowel Syndrome (IBS) in Germany
    13.2.1.3. Market Sales of Irritable Bowel Syndrome (IBS) by Products in Germany
    13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.2.2. France
    13.2.2.1. Market Size of Irritable Bowel Syndrome (IBS) in France
    13.2.2.2. Percentage Share of drugs marketed for Irritable Bowel Syndrome (IBS) in France
    13.2.2.3. Market Sales of Irritable Bowel Syndrome (IBS) by Products in France
    13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.2.3. Italy
    13.2.3.1. Market Size of Irritable Bowel Syndrome (IBS) in Italy
    13.2.3.2. Percentage Share of drugs marketed for Irritable Bowel Syndrome (IBS) in Italy
    13.2.3.3. Market Sales of Irritable Bowel Syndrome (IBS) by Products in Italy
    13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.2.4. Spain
    13.2.4.1. Market Size of Irritable Bowel Syndrome (IBS) in Spain
    13.2.4.2. Percentage Share of drugs marketed for Irritable Bowel Syndrome (IBS) in Spain
    13.2.4.3. Market Sales of Irritable Bowel Syndrome (IBS) by Products in Spain
    13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
  13.2.5. United Kingdom
    13.2.5.1. Market Size of Irritable Bowel Syndrome (IBS) in United Kingdom
    13.2.5.2. Percentage Share of drugs marketed for Irritable Bowel Syndrome (IBS) in United Kingdom
    13.2.5.3. Market Sales of Irritable Bowel Syndrome (IBS) by Products in United Kingdom
    13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
  13.3.1. Market Size of Irritable Bowel Syndrome (IBS) in Japan
  13.3.2. Percentage Share of drugs marketed for Irritable Bowel Syndrome (IBS) in Japan
  13.3.3. Market Sales of Irritable Bowel Syndrome (IBS) by Products in Japan
  13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. MARKET DRIVERS

15. MARKET BARRIERS

16. APPENDIX

17. REPORT METHODOLOGY

17.1. Sources

18. DELVEINSIGHT CAPABILITIES

19. DISCLAIMER

20. ABOUT DELVEINSIGHT

Indication Specific

LIST OF TABLES

Table 1: Total Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Irritable Bowel Syndrome (IBS) in United States (2016-2028)
Table 6: Diagnosed Cases of the Irritable Bowel Syndrome (IBS) in United States (2016-2028)
Table 7: Treatable Cases of the Irritable Bowel Syndrome (IBS) in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Irritable Bowel Syndrome (IBS) in Germany (2016-2028)
Table 11: Diagnosed Cases of the Irritable Bowel Syndrome (IBS) in Germany (2016-2028)
Table 12: Treatable Cases of the Irritable Bowel Syndrome (IBS) in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in France (2016-2028)
Table 14: Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) in France (2016-2028)
Table 15: Sex- Specific Cases of the Irritable Bowel Syndrome (IBS) in France (2016-2028)
Table 16: Diagnosed Cases of the Irritable Bowel Syndrome (IBS) in France (2016-2028)
Table 17: Treatable Cases of the Irritable Bowel Syndrome (IBS) in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Irritable Bowel Syndrome (IBS) in Italy (2016-2028)
Table 21: Diagnosed Cases of the Irritable Bowel Syndrome (IBS) in Italy (2016-2028)
Table 22: Treatable Cases of the Irritable Bowel Syndrome (IBS) in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Irritable Bowel Syndrome (IBS) in Spain (2016-2028)
Table 26: Diagnosed Cases of the Irritable Bowel Syndrome (IBS) in Spain (2016-2028)
Table 27: Treatable Cases of the Irritable Bowel Syndrome (IBS) in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) in UK (2016-2028)
Table 30: Sex- Specific Cases of the Irritable Bowel Syndrome (IBS) in UK (2016-2028)
Table 31: Diagnosed Cases of the Irritable Bowel Syndrome (IBS) in UK (2016-2028)
Table 32: Treatable Cases of the Irritable Bowel Syndrome (IBS) in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Irritable Bowel Syndrome (IBS) in Japan (2016-2028)
Table 36: Diagnosed Cases of the Irritable Bowel Syndrome (IBS) in Japan (2016-2028)
Table 37: Treatable Cases of the Irritable Bowel Syndrome (IBS) in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Irritable Bowel Syndrome (IBS) in USD MM (2016-2028)
Table 42:7MM- Market Share Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Irritable Bowel Syndrome (IBS) in USD MM (2016-2028)
Table 45: United States-Market Share Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Irritable Bowel Syndrome (IBS) in USD MM (2016-2028)
Table 48: Germany-Market Share Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Irritable Bowel Syndrome (IBS) in USD MM (2016-2028)
Table 51: France-Market Share Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Irritable Bowel Syndrome (IBS) in USD MM (2016-2028)
Table 54: Italy-Market Share Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Irritable Bowel Syndrome (IBS) in USD MM (2016-2028)
Table 57: Spain-Market Share Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Irritable Bowel Syndrome (IBS) in USD MM (2016-2028)
Table 60:UK-Market Share Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Irritable Bowel Syndrome (IBS) in USD MM (2016-2028)
Table 63: Japan-Market Share Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)

LIST OF FIGURES

Figure 1: Total Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Irritable Bowel Syndrome (IBS) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Irritable Bowel Syndrome (IBS) in United States (2016-2028)
Figure 7: Treatable Cases of the Irritable Bowel Syndrome (IBS) in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Irritable Bowel Syndrome (IBS) in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Irritable Bowel Syndrome (IBS) in Germany (2016-2028)
Figure 12: Treatable Cases of the Irritable Bowel Syndrome (IBS) in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) in France (2016-2028)
Figure 15: Sex- Specific Cases of the Irritable Bowel Syndrome (IBS) in France (2016-2028)
Figure 16: Diagnosed Cases of the Irritable Bowel Syndrome (IBS) in France (2016-2028)
Figure 17: Treatable Cases of the Irritable Bowel Syndrome (IBS) in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Irritable Bowel Syndrome (IBS) in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Irritable Bowel Syndrome (IBS) in Italy (2016-2028)
Figure 22: Treatable Cases of the Irritable Bowel Syndrome (IBS) in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Irritable Bowel Syndrome (IBS) in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Irritable Bowel Syndrome (IBS) in Spain (2016-2028)
Figure 27: Treatable Cases of the Irritable Bowel Syndrome (IBS) in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Irritable Bowel Syndrome (IBS) in UK (2016-2028)
Figure 31: Diagnosed Cases of the Irritable Bowel Syndrome (IBS) in UK (2016-2028)
Figure 32: Treatable Cases of the Irritable Bowel Syndrome (IBS) in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Irritable Bowel Syndrome (IBS) in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Irritable Bowel Syndrome (IBS) in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Irritable Bowel Syndrome (IBS) in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Irritable Bowel Syndrome (IBS) in Japan (2016-2028)
Figure 37: Treatable Cases of the Irritable Bowel Syndrome (IBS) in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Irritable Bowel Syndrome (IBS) in USD MM (2016-2028)
Figure 42:7MM- Market Share Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Irritable Bowel Syndrome (IBS) in USD MM (2016-2028)
Figure 45: United States-Market Share Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Irritable Bowel Syndrome (IBS) in USD MM (2016-2028)
Figure 48: Germany-Market Share Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Irritable Bowel Syndrome (IBS) in USD MM (2016-2028)
Figure 51: France-Market Share Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Irritable Bowel Syndrome (IBS) in USD MM (2016-2028)
Figure 54: Italy-Market Share Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Irritable Bowel Syndrome (IBS) in USD MM (2016-2028)
Figure 57: Spain-Market Share Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Irritable Bowel Syndrome (IBS) in USD MM (2016-2028)
Figure 60:UK-Market Share Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Irritable Bowel Syndrome (IBS) in USD MM (2016-2028)
Figure 63: Japan-Market Share Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Irritable Bowel Syndrome (IBS) by Therapies in USD MM (2016-2028)

Irritable Bowel Syndrome (IBS) - Market Insight, Epidemiology and Market Forecast - 2028

More Publications

Need Help?

Ask a Question

Market Reports